Study 132-03 is a Phase 2a, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of RSLV-132 in patients with lupus. The study will assess 64 patients with active skin disease and elevated RNA-containing autoantibodies and will be conducted across 20 centers in the United States. Study 132-03 completed enrollment in July 2019 and topline data from the trial are expected in the first quarter of 2020.
Study 132-04 was a double-blind, placebo-controlled study of RSLV-132 in patients with Sjögren’s syndrome (n=28). It was designed to explore the clinical efficacy of RSLV-132 in improving the symptoms associated with Sjögren’s syndrome, particularly fatigue. RSLV-132 significantly improved symptoms of fatigue as compared to placebo and was safe and well‐tolerated. Resolve plans to initiate a Phase 3 trial in Sjögren’s syndrome in 2020.